• Nine abstracts showcasing developments across inflammation & neuroinflammation, psychiatric disease, depression & more! We'll be at Booth No.1818.
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent
 

Alzheimer’s Disease

Alzheimer’s disease (AD) is a neurodegenerative disease that causes progressive and disabling impairment of cognitive functions including memory and attention. Alzheimer’s disease is also characterised by neuropsychiatric symptoms like apathy, social withdrawal, disinhibition, agitation and psychosis. Later stage symptoms also include sleep disturbances and motor deficits like dystonia, akathisia and parkinsonian symptoms. AD is now the sixth leading cause of death in the United States, representing a significant unmet medical need.

At Transpharmation, our multi-faceted approach combines the use of naturally occurring deficits in aged animals along with pharmacological intervention to mimic aspects of the disease such as cognitive deficits, and sleep disruption. Furthermore, using our extensive biomarker platform we can profile translational disease markers such as TAU/phospho-TAU in both rodent and human tissue (via our CNS biobank) and assess the role of neuroinflammatory markers, such as cytokines, chemokines and microglia in AD disease pathology.

Examples of the models we offer include:


pain1This list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.

Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk


Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design